{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:15:39Z","timestamp":1762175739272},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1984,6,1]],"date-time":"1984-06-01T00:00:00Z","timestamp":454896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1984,6]]},"DOI":"10.1007\/bf00401445","type":"journal-article","created":{"date-parts":[[2004,10,20]],"date-time":"2004-10-20T15:27:39Z","timestamp":1098286059000},"page":"39-42","source":"Crossref","is-referenced-by-count":6,"title":["Lack of response in nine patients with breast cancer treated with fibroblast interferon"],"prefix":"10.1007","volume":"13","author":[{"given":"U.","family":"Bruntsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Groos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. -J.","family":"Tigges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. H.","family":"Hofschneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. M.","family":"Gallmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0277-5379(81)80001-6","volume":"17","author":"A Billiau","year":"1981","unstructured":"Billiau A (1981) The clinical value of interferons as antitumor agents. Eur J Cancer Clin Oncol 17:949?967","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR2","first-page":"750","volume":"21","author":"E Borden","year":"1980","unstructured":"Borden E, Dao T, Holland J, Gutterman J, Merigan T (1980) Interferon in recurrent breast carcinoma: preliminary report of the American Cancer Society Clinical Trials Program. Proc Am Assoc Cancer Res 21:750","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CR3","first-page":"1080","volume":"307","author":"S Borgstr\u00f6m","year":"1982","unstructured":"Borgstr\u00f6m S, von Eyben FE, Flodgren P, Axelsson B, Sj\u00f6gren HO (1982) Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med 307:1080?1081","journal-title":"N Engl J Med"},{"key":"CR4","first-page":"159","volume-title":"Human interferon production and clinical use","author":"S Einhorn","year":"1977","unstructured":"Einhorn S, Strander H (1977) Interferon therapy for neoplastic disease in man. In: Stinebring WR, Chapple PI (eds) Human interferon production and clinical use. Plenum, New York, pp 159?174"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00320101","volume":"44","author":"U Fink","year":"1982","unstructured":"Fink U, Siegert W, Huhn D, Wilmanns W, Berdel WE, Emmerich B, Hutsteiner H, Wust I, Rastetter J, Theml H, Riethm\u00fcller G (1982) Fibroblasten-Interferon-Therapie (HU INF-BETA) bei Non-Hodgkin-Lymphomen (NHL) mit niedrigem Malignit\u00e4tsgrad: Vorl\u00e4ufige Ergebnisse. Blut 44:121?124","journal-title":"Blut"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/newbio236078a0","volume":"236","author":"I Gresser","year":"1972","unstructured":"Gresser I, Bourali-Maury C (1972) Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastases in mice. Nature New Biol 236:78?79","journal-title":"Nature New Biol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3181\/00379727-124-31672","volume":"124","author":"I Gresser","year":"1967","unstructured":"Gresser I, Coppey Y, Falcoff E, Fontaine D (1967) Interferon and murine leukemia. I. Inhibitory effect of interferon on development of Friend leukemia in mice. Proc Soc Exp Biol Med 124:84?91","journal-title":"Proc Soc Exp Biol Med"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1073\/pnas.63.1.51","volume":"63","author":"I Gresser","year":"1969","unstructured":"Gresser I, Bourali C, Levy JP (1969) Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 63:51?56","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-93-3-399","volume":"93","author":"JU Gutterman","year":"1980","unstructured":"Gutterman JU, Blumenschein GR, Alexanian RA, Yap HY, Buzdar AU, Cabanillas F, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S (1980) Leukocyte-interferon-induced regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93:399?406","journal-title":"Ann Intern Med"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.2.6.476","volume":"2","author":"EA Havell","year":"1972","unstructured":"Havell EA, Vil?ek J (1972) Production of high-titered interferon in cultures of human diploid cells. Antimicrob Agents Chemother 2:476?484","journal-title":"Antimicrob Agents Chemother"},{"key":"CR11","first-page":"286","volume":"308","author":"NO Hill","year":"1983","unstructured":"Hill NO, Pardue A, Khan A, Hill RW, Aleman C, Hilario R, Hill JM, Osther K (1983) Interferon and cimetidine for malignant melanoma. N Engl J Med 308:286","journal-title":"N Engl J Med"},{"key":"CR12","first-page":"213","volume-title":"Interferon Properties, mode of action, production, clinical application","author":"F Lampert","year":"1982","unstructured":"Lampert F, Berthold F, Treuner J, Niethammer D (1982) Therapeutical trial for neuroblastoma stage IV. In: Munk K, Kirchner H (eds) Interferon Properties, mode of action, production, clinical application. Karger, Basel, pp 213?216"},{"key":"CR13","first-page":"75","volume":"65","author":"TA McPherson","year":"1980","unstructured":"McPherson TA, Tan YH (1980) Phase I. Pharmacotoxicology study of human fibroblast interferon in human cancers. J Natl Cancer Inst 65:75?79","journal-title":"J Natl Cancer Inst"},{"key":"CR14","first-page":"205","volume-title":"Interferon. Properties, mode of action, production, clinical application","author":"D Niethammer","year":"1982","unstructured":"Niethammer D, Treuner J (1982) Experience with fibroblast-derived interferon as an antitumor agent. In: Munk K, Kirchner H (eds) Interferon. Properties, mode of action, production, clinical application. Karger, Basel, pp 205?212"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0277-5379(82)90240-1","volume":"18","author":"P Pouillart","year":"1982","unstructured":"Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, Falcoff E, Billiau A (1982) Administration of fibroblast interferon to patients with advanced breast cancer: Possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol 18:929?935","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(80)91308-2","volume":"I","author":"J Treuner","year":"1980","unstructured":"Treuner J, Niethammer D, Dannecker G, Hagmann R, Neef V, Hofschneider PH (1980) Successful treatment of nasopharyngeal carcinoma with interferon. Lancet I:817?818","journal-title":"Lancet"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01241277","volume":"20","author":"M Vandeputte","year":"1967","unstructured":"Vandeputte M, De Lafonteyne J, Billiau A, De Somer P (1967) Influence and production of interferon in Rauscher virus-infected mice. Arch Ges Virusforsch 20:235?245","journal-title":"Arch Ges Virusforsch"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1099\/0022-1317-13-1-185","volume":"13","author":"J Vil?ek","year":"1971","unstructured":"Vil?ek J, Varacalli F (1971) Sequential suppression by actinomycin D of interferon production and cellular resistance induced by poly I.C. J Gen Virol 13:185?188","journal-title":"J Gen Virol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00625042","volume":"106","author":"K Winkler","year":"1983","unstructured":"Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, G\u00f6bel U, Havers W, Henze G, Kinderfeld L, H\u00f6cker P, Jobke A, J\u00fcrgens H, Kabisch H, Landbeck G, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, W\u00fcst G (1983) Adjuvant chemotherapy in osteosarcoma ? effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. J Cancer Res Clin Oncol (Suppl) 106:1?7","journal-title":"J Cancer Res Clin Oncol (Suppl)"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00401445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00401445\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00401445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T22:17:45Z","timestamp":1554329865000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00401445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,6]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1984,6]]}},"alternative-id":["BF00401445"],"URL":"https:\/\/doi.org\/10.1007\/bf00401445","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,6]]}}}